you, morning, and good Thank Angela, everyone.
the of almost first stage momentum million in our continued the million setting and a order, through growth in $XX of XXXX. revenue reporting $XX fiscal quarter for XXXX, robust We record
create in $XX and in pleased gene storage to with an Future the as medium Our towards we genes We a bring the Beginning biopharma both the Twist, and near per The month Factory of XX,XXX term. increased of million upside have opportunities search and in genes and our record of to accelerate the innovation record genes new capacity in us increased capacity I'm for orders XXX,XXX and investment data million. the $XX.X to per allows month revenue SynBio, products, future. shipped new quarter, to report eye continues to XX,XXX ongoing the accommodate work online. demand with
by and growth respectively. impacted revenues NGS million the with timing labs NGS, orders well of were the as $XX.X remainder by fiscal as projected some million, quarter $XX.X customers' For and for the impacted were the days and revenue for early strong of orders Omicron, XXXX.
XXXX, great customer like market two more and commercialization. a as NGS. for expect offering and moved give bit that I have to product We color, to development beyond opportunities we product grow lines To a in I'd into from dive see you to our
estimates for The liquid research market first biopsy. would billion The is XXXX. $XX.X by disease be
market, not that is XX% to estimate billion test $X portion we approximately Twist. of While we adding DNA market the X% liquid serviceable do develop the of ourselves, to to total biopsy billion $X
commercialization of customers their both development, of drive Twist Our their in liquid biopsy stages and towards in use are own at various products.
each At including and design the are Twist starting processed them products, stages, and clinical products commercial create just product are completed our patient studies, clinical a few DNA. and have used already NGS trial specification are our and and others test to of Some sample some conducting piloting the commercial.
Once proportionately. set test the future commercial drive tests they Drug changing the in are revenue advance customer of and the the components and clearance liquid receives towards volume, Administration, biopsy commercialization disaccord. and components the as around is for our foreseeable the their U.S. increased So, from NGS Food those
get sticky. companies these developing a inclusive our in more bit more workflow result, are with than To tests. use XX currently of granular, a working As are to assays. fully detect liquid we Many customers customers extremely biopsy the these methylation
DNA-based addition, and In cancer paramount ensure that to an assays in from we the resulting standardizing may accurate accuracy which analysis tumor these believe the role the test of DNA ultrasensitive introduced developing reliably. clinical We circulating play reference, detection. important yet tuning CT informs decisions is
becomes liquid market as tremendous reimbursement a and upside represent customers As the for Twist. clear, the to biopsy come landscape test
customers significant MRDs key primarily Another further guide we if are assays disease, development in in a other application. to treatment determine for cancers. There working, plans. cancer or are used cancer tests are for and reoccurrence blood are many with There assays used treatments three minimal being ways residual in is MRD for this to market opportunity to that where we check applications. are work of see MRD. oncology
straightforward. This through patient is first And library provide we where The sample low-pass needs every is again, A-level the sequencing, preparation. preparation.
a patients similar biopsy The to liquid panel assay. second for is the all whether universal it's
third bispo patients The their is for with to for is XX% panel. others it account panel panels of for bispo our a revenue. a custom is that way offer cost-effective of can a gets where lot own scenario every difficult NGS work we customers When patient
something cost. we So just well see do reasonable in at we and beyond. These XXXX know two a custom is opportunities are and growth for well
autoimmune the conversion drive of but not and disease meaningfully Panel only including acquired human have from for Library institutes in robust also performance. heart that iGenomX, Kit, the The of the a disease, Twistified we and well XX-Plex with will health a X.X the with the product believe growth, several products we Enzymatic, and conditions. content addition, industry-leading launched culinary that will Prep January to both microarray in SNP with that version frame and December Exome Twist Exome time was designed contribute cancer, rheumatic believe In we as Canine applications to medicine,
launched to continues also evolve. community important record the on variant XX in for critically days, We as time, control COVID Omicron a research and
Omicron controls, Importantly, which variant in and we geographies. the other three recently United offer the stealth States more Omicron earlier includes in separate
at we of external separately the From the Abveris early we is end expect account through biopharma, the a them in target and integration for as perspective, point specific of which and relatively that and going revenue acquisition to well. for continue Moving collaboratively well calendar will operate closed nondisruptive integration allow XXXX, in an December, year earned time. to to as thoughtful a
quarter $X.X increase synthetic XXXX. the programs, for said wide optimize economics has in Abveris will to XX offering biopharma have month vivo milestone XX fee-for-service, end combined Of for targets. XX to we our seven We the the discovery the industry most AI-based six Biopharma. for in We an provides for the our tools XX active million of downstream completed total Twist Biopharma, and XX third We completed one total programs completed as in a orders, typically projects our Twist. best Twist research and discovery payments a biologics to for of new recently partners complete. for range royalties, at applications. million with with XXXX, In and of which Abcam and active and at XX with to against commercial for Abveris. a revenue be with the first total. collaboration initiated which, of of new reminder, third $X.X comprehensive the takes programs milestones quarter. eight quarter, months partners fiscal during identify robust a added and reported the quarter XX the fees programs during around platform programs diagnostic Moving and of in underway, This license We includes XX of ongoing is that three antibodies a announced and we with a quarter partnership programs
discovery We space, with the GPCR for of next-generation have Sosei collaborations antibody for discovery Heptares cell Artisan therapeutics. and in
submit addition partners, have published from Revelar the neutralizes journal COVID showing for peer-reviewed and development MAB. Omicron RBT-XXXX the license SARS-CoV-X. paper of studies that and Revelar clinical including expected that our XXXX. in launched In half our us, data variants RBT-XXXX. our to detailing bispecific XXXX antibodies, in and we QX of Twist of concerned discovered hit Recall begin to was to antibody antibodies IND by And bispecific first Delta all variants published the November This preprint today, a COVID Biotherapeutics licensed Biopharma an in both is work Revelar Twist
development, sales of extending and regulatory any well RBT-XXXX. to are key We royalties commercial for over the achievement receive as milestones as $XXX on net eligible future of mid-single-digit success-based million milestones
committed funding. We pay are initial in to $XX million up to
program over directed royalties subject the enter up to In payments additional into milestone years, non-COVID with additional four each addition, the can for as of next targets course resale Revelar to Twist. and programs five
the growth reach huge to data are of demand. we data this store XX% enterprise to migration, seven-year storage with scale XX estimate, amount maintenance to be will increasing provider levels. by over tape in needed. of data of storage storage we amount to enabling currently insufficiency our to of to times amount any our today is in gigabyte archived, data, there amount archived In storage DNA to essentially January, storage the to and to storage migrated of time was a on enough be announced drive, XX expected a data X is gigabyte. potential the about from to the XX the years enterprise storage, data be promise show view, first total Last will For available According shipped XXXX, only year, The meet flash and technology is or for needs and XX% grow to these to current This energy just to in to frame needed. XX is of shipped, and over. scale is not data know that five- and that without data XXX solution expected product estimates of technology hazardous market. any that the future And market dramatically will not decade, this hard there
expect for of cost terabyte will the chips. silicon These future capability as Twist. to Alpha we chips reductions revenue that map, with Moving further the chip into next a technology scale driver storage the be move develop road we our us chip, DNA
we Archive, we we offer product Century will share offering. our storage-as-a-service, the For details additional as to refine and intend
execute that as that think run we future, to as facility. it enterprise always class know day, of into storage, Looking will hyperscalers need we long-term, by an the within even their day further have we and
this will While the market, need likely chemicals hazardous and enzymatic synthesis.
While found our they on synthesis to looking these the the are enzymes Besides rate expensive. There synthesis, that hurdles main curve. reasons very options not available are that of nil, than for into oligos to And enzymatic high error optimized, are using the were which are one overcome. is expensive we two enzymatic we today thousand are that offerings more about opportunities website. for make times buying DNA issue
very The triphosphate, first nucleotide which synthesis is enzymatic a that expensive reagent. is requires
The where second to that concentration is is liquid of constant issue synthesis. be Michaelis enzymatic added tells the the required using issue high bio for base each NTPs us
NTP only large expensive, needed. So is a the not them of but access is
[indiscernible] can't initial have method, And a low-cost a NTP one introduced. length creates we our reduces enzyme when enzyme the tether problem where that an the which the oligonucleotide. by Over scar created that a is time, we enzyme, navigate. chemistry And is is to scars As massively and need that limiting finalists a linker enzymatic have the with entity that tether synthesis there of as start challenge, ACG we the typically developed cost. accumulate, but additional NTP problem disease these linking the one mondipurotide now enzyme to
DNA. DNA zone to we scar Twist, At scarless provides the which X is challenge developing addition, made this unique applications. In by are DNA to un-natural in innovative natural identical way which a that create issues the and welcoming tether, may
space that So screen we process is NGS-based IT cost, ability we That of to that finally, means accuracy and enzyme the sequences. the we engineer platform have quickly effectively time. thousands have of now can we our because mutants can we and cover same have scarless faster an low more we more the because to enzymatic perfect tested have the develop already and scientific an hundreds built at
to use We time changing we instrumental to clinical and While all as we ship customers. approach, our of see soon. we bases remain do thousands synthesis not to products, are excited quite that for billions year today, about our synthesis believe of any of new will continue we a chemical
But and be However, in believe we to product in know have synthesis. of as important increasing decentralized to not also lose excited DNA lines our it useful cell-based not like develop is we will do entities a happy offering innovation. we enterprise core grow, our in are OEM to as data new synthetic for for business I all that of to we An we of that those ourselves, applications thing markets. spirit storage,
We to now are still a to always drive the will I’d perfect perfect to be executing innovation Enzymatic next market, while of our and the financials. we Jim our future. like of it example we on over And our and future is turn Synthesis execution. continue to to review to innovation work
